Which has better earnings and valuation, PRAX or RVMD?

Revolution Medicines is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Praxis Precision Medicines N/A N/A -$303.27M -$13.37 N/A Revolution Medicines N/A N/A -$1.13B -$7.07 N/A

Is PRAX or RVMD more profitable?

Praxis Precision Medicines' return on equity of -43.02% beat Revolution Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Revolution Medicines N/A -83.22% -59.06%

Does the media favor PRAX or RVMD?

In the previous week, Praxis Precision Medicines had 12 more articles in the media than Revolution Medicines. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 14 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.36 beat Praxis Precision Medicines' score of -0.08 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 3 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Revolution Medicines 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ONC or PRAX?

In the previous week, Praxis Precision Medicines had 17 more articles in the media than BeOne Medicines. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 9 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.92 beat Praxis Precision Medicines' score of -0.08 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 3 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BNTX or PRAX?

In the previous week, Praxis Precision Medicines had 21 more articles in the media than BioNTech. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 5 mentions for BioNTech. BioNTech's average media sentiment score of 0.54 beat Praxis Precision Medicines' score of -0.08 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 3 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to INSM or PRAX?

In the previous week, Insmed had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 30 mentions for Insmed and 26 mentions for Praxis Precision Medicines. Insmed's average media sentiment score of 0.84 beat Praxis Precision Medicines' score of -0.08 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 19 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 3 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ROIV or PRAX?

In the previous week, Praxis Precision Medicines had 14 more articles in the media than Roivant Sciences. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 12 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.17 beat Praxis Precision Medicines' score of -0.08 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 3 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Praxis Precision Medicines (PRAX) Competitors

$250.10 -3.90 (-1.53%)

As of 03:26 PM Eastern

Compare

PRAX vs. RVMD, ONC, BNTX, INSM, and ROIV

Should you buy Praxis Precision Medicines stock or one of its competitors? MarketBeat compares Praxis Precision Medicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Praxis Precision Medicines include Revolution Medicines (RVMD), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

How does Praxis Precision Medicines compare to Revolution Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Revolution Medicines is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$13.37	N/A
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A

Praxis Precision Medicines' return on equity of -43.02% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Revolution Medicines	N/A	-83.22%	-59.06%

Praxis Precision Medicines has a beta of 2.71, meaning that its share price is 171% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Praxis Precision Medicines presently has a consensus price target of $572.72, suggesting a potential upside of 128.99%. Revolution Medicines has a consensus price target of $123.72, suggesting a potential downside of 16.37%. Given Praxis Precision Medicines' higher probable upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Praxis Precision Medicines had 12 more articles in the media than Revolution Medicines. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 14 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.36 beat Praxis Precision Medicines' score of -0.08 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Praxis Precision Medicines beats Revolution Medicines on 8 of the 14 factors compared between the two stocks.

How does Praxis Precision Medicines compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

BeOne Medicines presently has a consensus target price of $390.00, suggesting a potential upside of 44.80%. Praxis Precision Medicines has a consensus target price of $572.72, suggesting a potential upside of 128.99%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95

In the previous week, Praxis Precision Medicines had 17 more articles in the media than BeOne Medicines. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 9 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.92 beat Praxis Precision Medicines' score of -0.08 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, suggesting that its share price is 171% more volatile than the broader market.

BeOne Medicines has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.74B	5.15	$286.93M	$4.47	60.25
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$13.37	N/A

BeOne Medicines has a net margin of 8.94% compared to Praxis Precision Medicines' net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

BeOne Medicines beats Praxis Precision Medicines on 9 of the 16 factors compared between the two stocks.

How does Praxis Precision Medicines compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Praxis Precision Medicines has lower revenue, but higher earnings than BioNTech. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.81B	7.77	-$1.29B	-$5.88	N/A
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$13.37	N/A

Praxis Precision Medicines has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

BioNTech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market.

BioNTech currently has a consensus price target of $129.56, indicating a potential upside of 50.27%. Praxis Precision Medicines has a consensus price target of $572.72, indicating a potential upside of 128.99%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Praxis Precision Medicines had 21 more articles in the media than BioNTech. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 5 mentions for BioNTech. BioNTech's average media sentiment score of 0.54 beat Praxis Precision Medicines' score of -0.08 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Praxis Precision Medicines beats BioNTech on 8 of the 15 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Insmed?

Insmed (NASDAQ:INSM) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Praxis Precision Medicines has lower revenue, but higher earnings than Insmed. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	33.78	-$1.28B	-$5.75	N/A
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$13.37	N/A

Praxis Precision Medicines has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Praxis Precision Medicines' return on equity of -43.02% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Insmed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, meaning that its share price is 171% more volatile than the broader market.

Insmed presently has a consensus target price of $212.50, suggesting a potential upside of 124.81%. Praxis Precision Medicines has a consensus target price of $572.72, suggesting a potential upside of 128.99%. Given Praxis Precision Medicines' higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Insmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95

67.8% of Praxis Precision Medicines shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Insmed had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 30 mentions for Insmed and 26 mentions for Praxis Precision Medicines. Insmed's average media sentiment score of 0.84 beat Praxis Precision Medicines' score of -0.08 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	19 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Praxis Precision Medicines beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Roivant Sciences has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market.

Roivant Sciences presently has a consensus price target of $33.59, indicating a potential upside of 17.15%. Praxis Precision Medicines has a consensus price target of $572.72, indicating a potential upside of 128.99%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95

In the previous week, Praxis Precision Medicines had 14 more articles in the media than Roivant Sciences. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 12 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.17 beat Praxis Precision Medicines' score of -0.08 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	9 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Roivant Sciences has higher revenue and earnings than Praxis Precision Medicines. Roivant Sciences is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,496.81	-$299.77M	-$0.60	N/A
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$13.37	N/A

Praxis Precision Medicines has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Summary

Praxis Precision Medicines beats Roivant Sciences on 9 of the 16 factors compared between the two stocks.

Get Praxis Precision Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRAX vs. The Competition

Export

Metric	Praxis Precision Medicines	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.97B	$3.30B	$6.44B	$12.09B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	-18.71	18.91	23.80	23.78
Price / Sales	N/A	175.61	479.35	86.31
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	7.18	8.05	10.36	6.80
Net Income	-$303.27M	$23.89M	$3.57B	$337.51M
7 Day Performance	-25.38%	-5.80%	-1.27%	-2.64%
1 Month Performance	-24.22%	2.07%	3.17%	1.90%
1 Year Performance	461.28%	36.48%	23.59%	26.94%

Praxis Precision Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRAX Praxis Precision Medicines	2.8802 of 5 stars	$250.11 -1.5%	$572.72 +129.0%	+470.0%	$6.97B	N/A	N/A	110
RVMD Revolution Medicines	2.1234 of 5 stars	$163.68 +3.9%	$122.78 -25.0%	+263.2%	$33.48B	N/A	N/A	250	High Trading Volume
ONC BeOne Medicines	4.6385 of 5 stars	$279.68 -2.9%	$389.15 +39.1%	+5.6%	$31.59B	$5.34B	62.57	12,000
BNTX BioNTech	3.8908 of 5 stars	$91.70 -4.4%	$129.56 +41.3%	-18.8%	$23.19B	$2.81B	N/A	7,807	Analyst Forecast
INSM Insmed	3.7435 of 5 stars	$106.03 -0.8%	$210.95 +99.0%	+28.0%	$23.17B	$606.42M	N/A	1,664	News Coverage Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRAX) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Praxis Precision Medicines (PRAX) Competitors

PRAX vs. RVMD, ONC, BNTX, INSM, and ROIV

How does Praxis Precision Medicines compare to Revolution Medicines?

Summary

How does Praxis Precision Medicines compare to BeOne Medicines?

Summary

How does Praxis Precision Medicines compare to BioNTech?

Summary

How does Praxis Precision Medicines compare to Insmed?

Summary

How does Praxis Precision Medicines compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX vs. The Competition

Praxis Precision Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Praxis Precision Medicines (PRAX) Competitors

PRAX vs. RVMD, ONC, BNTX, INSM, and ROIV

How does Praxis Precision Medicines compare to Revolution Medicines?

Do institutionals & insiders have more ownership in PRAX or RVMD?

Which has better earnings and valuation, PRAX or RVMD?

Is PRAX or RVMD more profitable?

Which has more risk and volatility, PRAX or RVMD?

Do analysts prefer PRAX or RVMD?

Does the media favor PRAX or RVMD?

Summary

How does Praxis Precision Medicines compare to BeOne Medicines?

Do analysts recommend ONC or PRAX?

Does the media refer more to ONC or PRAX?

Which has more volatility & risk, ONC or PRAX?

Which has preferable valuation & earnings, ONC or PRAX?

Is ONC or PRAX more profitable?

Do insiders & institutionals have more ownership in ONC or PRAX?

Summary

How does Praxis Precision Medicines compare to BioNTech?

Which has better earnings & valuation, BNTX or PRAX?

Is BNTX or PRAX more profitable?

Which has more volatility & risk, BNTX or PRAX?

Do analysts prefer BNTX or PRAX?

Do insiders & institutionals have more ownership in BNTX or PRAX?

Does the media refer more to BNTX or PRAX?

Summary

How does Praxis Precision Medicines compare to Insmed?

Which has higher valuation and earnings, INSM or PRAX?

Is INSM or PRAX more profitable?

Which has more volatility & risk, INSM or PRAX?

Do analysts prefer INSM or PRAX?

Do institutionals and insiders believe in INSM or PRAX?

Does the media refer more to INSM or PRAX?

Summary

How does Praxis Precision Medicines compare to Roivant Sciences?

Do insiders & institutionals have more ownership in ROIV or PRAX?

Which has more risk and volatility, ROIV or PRAX?

Do analysts rate ROIV or PRAX?

Does the media favor ROIV or PRAX?

Which has preferable earnings & valuation, ROIV or PRAX?

Is ROIV or PRAX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX vs. The Competition

Praxis Precision Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools